NRIX: Bull Flag detected on 28 Aug 2026

NRIX is forming a bull flag pattern with a structure score of 14.4 and breakout score of 12.1, indicating solid technical quality. The stock is currently trading at $26.88, positioned just 4.78% below its 52-week high and 228% above its 52-week low, reflecting strong uptrend momentum. Key support sits at $21.23 while resistance is at $25.08. Volume remains elevated at 1.18x average (1.26M shares vs 1.07M avg), supporting the pattern's credibility. RSI at 62.09 shows room to extend higher without overbought extremes. The overall score of 73.9 and 73.53% win probability suggest this is a high-quality technical setup with favorable breakout conditions.

Nurix entered a global collaboration with Roche for bexobrutideg in June 2026 with potential total payments of up to $2.3 billion, including a $700 million upfront payment. This deal represents a major de-risking catalyst that drove sentiment shift. The company's BTK degrader bexobrutideg showed 83% objective response rate and median progression-free survival of 22.1 months in heavily pretreated relapsed/refractory CLL patients. Most recently on August 4, 2026, Nurix earned a $10 million milestone payment from Sanofi following initiation of a Phase 1 trial for STAT6 degrader SAR448272. Q2 2026 showed net loss of $89.5M against revenue of $9.0 million, with cash position of $443.5 million plus pro-forma $1.14 billion including Roche upfront. The sector regime is bullish (0.84 score), creating tailwinds for biotech assets with clinical validation.

A successful bull flag breakout targets $27.77 based on the conservative measured move—a 3.3% advance from current levels. The pattern suggests breakout would require volume confirmation above the current 1.26M share baseline to validate the move. Invalidation occurs at key support of $21.23, representing a 21% downside risk from current price. With 73.53% win probability, historical data shows favorable odds for upside extension. MACD histogram at -0.1178 is slightly negative but not deeply bearish, indicating momentum is constructive though not yet fully engaged. Volume ratio of 1.18x provides adequate confirmation for continuation.

Clinical-stage biotech carries binary event risk around Phase 3 trial readouts (DAYBreak CLL-306 underway) and FDA approval decisions expected in 2026-2027. Q2 net loss was $89.5 million against minimal $9.0 million revenue, indicating steep cash burn despite improved balance sheet from Roche deal. High volatility at 32.96% over 20 days paired with beta of 0.89 creates swing risk typical of biotech; stock can reverse sharply on trial setbacks. Positive feedback loop from recent collaboration success could create crowding; downside acceleration below $21.23 could be violent given thin institutional float. No analyst downgrades detected, but Roche's co-development involvement introduces execution risk on timelines and regulatory strategy.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.